胰岛素抵抗相关疾病的血清蛋白质组学:区分MASLD、脂肪营养不良与胰岛素受体缺陷
本研究采用SomaScan蛋白质组学技术,比较了30例脂肪营养不良(LD)、29例胰岛素受体致病性变异(INSR)和16例代谢功能障碍相关脂肪性肝病(MASLD)患者的空腹血清蛋白质组。结果显示,INSR的蛋白质组谱与其他组明显分离,而MASLD与LD相似,尤其在代谢、肝损伤和纤维化相关蛋白上。部分蛋白在INSR和LD中较MASLD独特升高,如凝血因子IX和肝脏表达抗菌肽2,且其血清水平与肝脏表达相关。
要点
- MASLD与LD的血清蛋白质组特征相似,提示肝病进展驱动因素可能相近。
- INSR的蛋白质组谱与MASLD和LD明显不同,尽管均存在高胰岛素血症和胰岛素抵抗。
- 凝血因子IX和肝脏表达抗菌肽2在INSR和LD中独特升高,与肝脏表达相关。
核心结论
- MASLD与LD共享部分蛋白质组特征,提示相似的肝病进展驱动因素。
- INSR具有独特的蛋白质组谱,关键肝源性蛋白在MASLD、INSR和LD间存在差异。
研究设计与样本
- 单中心研究,使用SomaScan检测空腹血清蛋白质组,纳入30例LD、29例INSR和16例MASLD患者。
- 关键靶点在19例MASLD患者的肝转录组和HepG2细胞中评估。
主要发现
- 6412种蛋白质中,567种在至少两组间存在差异。
- 蛋白质组谱清晰区分INSR与其他组,而MASLD与LD相似,主要涉及代谢、肝损伤和纤维化相关蛋白。
- 凝血因子IX和肝脏表达抗菌肽2在INSR和LD中较MASLD独特升高,血清水平与肝脏表达相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to obesity, metabolic syndrome, and insulin resistance (IR). In IR associated with obesity or lipodystrophy (LD), caused by missing adipose tissue, hyperinsulinemia stimulates hepatic lipogenesis, causing steatotic liver disease (SLD). In contrast, insulin receptor pathogenic variants (INSR), despite hyperinsulinemia and IR, do not promote hepatic lipogenesis and steatosis. We aimed to understand SLD pathophysiology by comparing serum proteomic signatures of MASLD, LD, and INSR. METHODS: Single-center study of fasting serum proteome using SomaScan assay in 30 LD, 29 INSR, and 16 people with MASLD. Key targets were assessed in the hepatic transcriptome of patients with MASLD (n = 19) and in HepG2 cells. RESULTS: Of 6412 proteins, 567 differed between at least 2 groups. The proteome profiles clearly separated INSR from the other groups, whereas MASLD and LD displayed similarity, primarily in proteins involved in metabolism, liver injury, and fibrosis. Several proteins were uniquely elevated in INSR and LD compared to MASLD, particularly Factor IX and liver-expressed antimicrobial peptide 2. Serum levels of Factor IX and liver-expressed antimicrobial peptide 2 correlated with their hepatic expression, with in vitro expression unaffected by leptin, insulin, or glucose treatment. CONCLUSION: This first comparative proteomics study identified shared and unique pathways in IR disorders. MASLD and LD share features, suggesting similar drivers of liver disease progression. Key liver-derived proteins differ between MASLD, INSR, and LD because of unique disorder features. We demonstrate the utility of proteomics and rare disorder studies in interrogating pathogenesis of common disorders like MASLD.
引用
- Mironova M, Wing A, Abel BS, et al. Serum Proteomics of Insulin Resistance Disorders Distinguish MASLD From Lipodystrophy and Insulin Receptor Defects. J Clin Endocrinol Metab. 2026. PMID: 41058075. doi:10.1210/clinem/dgaf516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。